Peripheral interactions between cannabinoid and opioid systems contribute to the antinociceptive effect of crotalphine

British Journal of Pharmacology

Volumn 171, Issue 4, 2014, Pages 961-972

  MacHado, F C ^a,b   Zambelli, V O ^a   Fernandes, A C O ^a   Heimann, A S ^c   Cury, Y ^a   Picolo, G ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Proteimax Biotechnology ^*  (Brazil)

Author keywords

antinociception; cannabinoid opioid interaction; CB 2 cannabinoid receptors; crotalphine; dynorphin A; endogenous opioid release

Indexed keywords

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR AGONIST; CROTALPHINE; DYNORPHIN A; OPIATE RECEPTOR; PROSTAGLANDIN E2; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HYPERALGESIA; IMMUNOFLUORESCENCE TEST; MALE; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; PROTEIN SECRETION; RAT;

ANTINOCICEPTION; CANNABINOID-OPIOID INTERACTION; CB2 CANNABINOID RECEPTORS; CROTALPHINE; DYNORPHIN A; ENDOGENOUS OPIOID RELEASE;

ANALGESICS; ANIMALS; CANNABINOID RECEPTOR ANTAGONISTS; DINOPROSTONE; HYPERALGESIA; INDOLES; MALE; OPIOID PEPTIDES; PEPTIDES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2; SKIN;

EID: 84893147310     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12488     Document Type: Article

References (53)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, Spedding M, Peters JA, Harmar AJ, and, CGTP Collaborators, (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 1449-1867.
2. Ameri A, (1999). The effects of cannabinoids on the brain. Prog Neurobiol 58: 315-348.
3. Anand P, Whiteside G, Fowler CJ, Hohmann AG, (2009). Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 60: 255-266.
4. Antonijevic I, Mousa SA, Schafer M, Stein C, (1995). Perineurial defect and peripheral opioid analgesia in inflammation. J Neurosci 15: 165-172.
5. Ashton JC, Friberg D, Darlington CL, Smith PF, (2006). Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 396: 113-116.
6. 2) immune regulation in health and disease. Immunol Res 51: 26-38.
7. Cabot PJ, (2001). Immune-derived opioids and peripheral antinociception. Clin Exp Pharmacol Physiol 28: 230-232.
8. Cabot PJ, Carter L, Gaiddon C, Zhang Q, Schafer M, Loeffler JP, et al. (1997). Immune cell-derived beta-endorphin. Production, release, and control of inflammatory pain in rats. J Clin Invest 100: 142-148.
9. Cabot PJ, Carter L, Schafer M, Stein C, (2001). Methionine-enkephalin-And Dynorphin A-release from immune cells and control of inflammatory pain. Pain 93: 207-212.
10. Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, et al. (2004). Cultured rat microglial cells synthesize the endocannabinoid 2-Arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 65: 999-1007.
11. Chavkin C, James IF, Goldstein A, (1982). Dynorphin is a specific endogenous ligand of the kappa opioid receptor. Science 215: 413-415.
12. Cichewicz DL, (2004). Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74: 1317-1324.
13. Desroches J, Beaulieu P, (2010). Opioids and cannabinoids interactions: involvement in pain management. Curr Drug Targets 11: 462-473.
14. Farquhar-Smith WP, Egertova M, Bradbury EJ, McMahon SB, Rice AS, Elphick MR, (2000). Cannabinoid CB(1) receptor expression in rat spinal cord. Mol Cell Neurosci 15: 510-521.
15. da Fonseca Pacheco D, Klein A, de Castro Perez A, da Fonseca Pacheco CM, de Francischi JN, Duarte ID, (2008). The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br J Pharmacol 154: 1143-1149.
16. Gad S, Weil C, (1989). Statistics for toxinologists. In:, Hayer A, (ed.). Principles and Methods of Toxicology. Raven Press Ltd: New York, pp. 435-483.
17. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
18. Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A, (2006). Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 1071: 10-23.
19. Graham ES, Ashton JC, Glass M, (2009). Cannabinoid receptors: a brief history and 'what's hot'. Front Biosci 14: 944-957.
20. Gupta A, Decaillot FM, Gomes I, Tkalych O, Heimann AS, Ferro ES, et al. (2007). Conformation state-sensitive antibodies to G-protein-coupled receptors. J Biol Chem 282: 5116-5124.
21. Gutierrez VP, Konno K, Chacur M, Sampaio SC, Picolo G, Brigatte P, et al. (2008). Crotalphine induces potent antinociception in neuropathic pain by acting at peripheral opioid receptors. Eur J Pharmacol 594: 84-92.
22. + channels are involved in the antinociceptive effect of crotalphine on neuropathic pain in rats. Behav Pharmacol 23: 14-24.
23. Hadley ME, Haskell-Luevano C, (1999). The proopiomelanocortin system. Ann N Y Acad Sci 885: 1-21.
24. Hassan AH, Pzewlocki R, Herz A, Stein C, (1992). Dynorphin, a preferential ligand for kappa-opioid receptors, is present in nerve fibers and immune cells within inflamed tissue of the rat. Neurosci Lett 140: 85-88.
25. 1 cannabinoid receptors. Proc Natl Acad Sci U S A 104: 20588-20593.
26. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC, (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.
27. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. (2005). CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102: 3093-3098.
28. Katsuyama S, Mizoguchi H, Kuwahata H, Komatsu T, Nagaoka K, Nakamura H, et al. (2013). Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception. Eur J Pain 17: 664-675.
29. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
30. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, et al. (2003). The cannabinoid system and immune modulation. J Leukoc Biol 74: 486-496.
31. Konno K, Picolo G, Gutierrez VP, Brigatte P, Zambelli VO, Camargo AC, et al. (2008). Crotalphine, a novel potent analgesic peptide from the venom of the South American rattlesnake Crotalus durissus terrificus. Peptides 29: 1293-1304.
32. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
33. Mackie K, (2008). Signaling via CNS cannabinoid receptors. Mol Cell Endocrinol 286: S60-S65.
34. Obara I, Parkitna JR, Korostynski M, Makuch W, Kaminska D, Przewlocka B, et al. (2009). Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain. Pain 141: 283-291.
35. Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, Meozzi PA, et al. (2006). Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074: 514-536.
36. Parolaro D, Rubino T, Vigano D, Massi P, Guidali C, Realini N, (2011). Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr Drug Targets 11: 393-405.
37. Picolo G, Cury Y, (2004). Peripheral neuronal nitric oxide synthase activity mediates the antinociceptive effect of Crotalus durissus terrificus snake venom, a delta- and kappa-opioid receptor agonist. Life Sci 75: 559-573.
38. Picolo G, Giorgi R, Cury Y, (2000). delta-opioid receptors and nitric oxide mediate the analgesic effect of Crotalus durissus terrificus snake venom. Eur J Pharmacol 391: 55-62.
39. Piomelli D, (2003). The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4: 873-884.
40. Pugh G Jr, Smith PB, Dombrowski DS, Welch SP, (1996). The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther 279: 608-616.
41. Randall LO, Selitto JJ, (1957). A method for measurement of analgesia activity on inflamed tissue. Arch Inst Pharmacodyn 111: 209-219.
42. Schauer E, Trautinger F, Kock A, Schwarz A, Bhardwaj R, Simon M, et al. (1994). Proopiomelanocortin-derived peptides are synthesized and released by human keratinocytes. J Clin Invest 93: 2258-2262.
43. Sehgal N, Smith H, Manchikanti L, (2011). Peripherally acting opioids and clinical implications for pain control. Pain Physician 14: 249-258.
44. Smith PB, Welch SP, Martin BR, (1994). Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 268: 1381-1387.
45. Stein C, (1993). Peripheral mechanisms of opioid analgesia. Anesth Analg 76: 182-191.
46. Stein C, Lang LJ, (2009). Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol 9: 3-8.
47. Stein C, Hassan AH, Przewlocki R, Gramsch C, Peter K, Herz A, (1990). Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci U S A 87: 5935-5939.
48. Su TF, Zhang LH, Peng M, Wu CH, Pan W, Tian B, et al. (2011). Cannabinoid CB2 receptors contribute to upregulation of β-endorphin in inflamed skin tissues by electroacupuncture. Mol Pain 7: 98.
49. Svizenska I, Dubovy P, Sulcova A, (2008). Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures-A short review. Pharmacol Biochem Behav 90: 501-511.
50. 1 cannabinoid receptor. J Mol Endocrinol 44: 75-85.
51. Welch SP, (2009). Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry 21: 143-151.
52. Zimmermann M, (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110.
53. Zogopoulos P, Vasileiou I, Patsouris E, Theocharis SE, (2013). The role of endocannabinoids in pain modulation. Fundam Clin Pharmacol 27: 64-80.